Figure 7.
![Semisynthetic glycoconjugates of N. meningitidis serogroup X [63] and C [67].](https://port.silverchair-cdn.com/port/content_public/journal/biochemsoctrans/49/5/10.1042_bst20210766/1/bst-2021-0766c.07.png?Expires=1716642734&Signature=BpCyD-s5E3y5O2UWWEeRekPa1jt4sn49~wKW-dovIsN9UfralBiDX9FDwXKQYVzqNb~W4rLKYw2k90jERy6vY7Lrm3-pTlm6Ch~xGT0xmM6jtbFT666oYh93CbYWpm0tWQzioQ640XBnuqWq8dFmpXhS4yRSx60r2iYzZznt8z1W7UsTSSG5pgyWeCdDy9JoZ5anCwZUWEHZu~ygATQVrkfh2nN1aBz4BbeuzNTHsfMWEK8i4RecxvwpBm~o2u~pWd1TI7Ng0O7qz6u9ueJWtSbPswhgEv~OOoFcuBJHi3rkCgqXwu57in20F7JUgdIxB6gFq2ISLLPesE2oej9apw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
The structure of a glycotope and a glycoconjugate vaccine candidate against Neisseria meningitidis.
Semisynthetic glycoconjugates of N. meningitidis serogroup X [63] and C [67].
Semisynthetic glycoconjugates of N. meningitidis serogroup X [63] and C [67].